An Overview of Genetic Biomarkers Influencing Drug Response and Efficacy in Specific Populations
DOI:
https://doi.org/10.29070/6qgge237Keywords:
Genetic biomarkers, Pharmacogenetics, Drug response variability, Personalized medicine, CYP450 enzymes, Drug transporters, Pharmacokinetics, Pharmacodynamics, Population-specific polymorphisms, Adverse drug reactions (ADRs), Therapeutic efficacy, CYP2D6 polymorphism, CYP2C19 polymorphism, SLCO1B1 variants, Thiopurine toxicity, Warfarin dosing, Statin-induced myopathy, Genetic diversity, Clinical pharmacogenomics, Healthcare disparitiesAbstract
Genetic biomarkers are pivotal in determining drug metabolism, efficacy, and toxicity. These biomarkers include variations in genes encoding enzymes, transporters, and drug targets that modulate pharmacokinetics and pharmacodynamics. This paper explores the role of genetic biomarkers in diverse populations, emphasizing their clinical relevance and integration into personalized medicine. We also examine population-specific genetic variations and their implications for reducing healthcare disparities.
References
Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526(7573), 343–350.
[Explores the integration of pharmacogenetics into clinical practice, with examples of biomarkers influencing drug response.]
Klein, T. E., et al. (2020). PharmGKB: Integrating pharmacogenomics into clinical practice. Clinical Pharmacology & Therapeutics, 107(2), 388–395.
[Details the role of PharmGKB in cataloging pharmacogenomic data and its application in clinical settings.]
Caudle, K. E., et al. (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2D6 and CYP2C19 Genotypes. Clinical Pharmacology & Therapeutics, 95(4), 376–382.
[Provides specific clinical recommendations for drugs metabolized by CYP2D6 and CYP2C19.]
Daly, A. K. (2010). Pharmacogenomics of adverse drug reactions. Genome Medicine, 2(11), 66.
[Reviews the genetic factors underlying adverse drug reactions and their implications for drug safety.]
Wang, L., et al. (2011). From discovery to practice: Implementation of pharmacogenomics in clinical settings. Molecular Diagnosis & Therapy, 15(3), 165–175.
[Discusses pathways to integrate pharmacogenomics research into healthcare delivery.]
Hoffmeyer, S., et al. (2000). Function of P-glycoprotein in the blood-brain barrier: Effect of genetic polymorphisms. The Journal of Clinical Investigation, 107(4), 431–437.
[Seminal work on ABCB1 polymorphisms and their impact on drug transport.]
International Warfarin Pharmacogenetics Consortium (IWPC). (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. The New England Journal of Medicine, 360(8), 753–764.
[Landmark study on warfarin dosing algorithms based on genetic and clinical data.]
Ramsey, L. B., et al. (2014). TPMT testing for thiopurine therapy: Challenges and opportunities. Pharmacogenomics, 15(6), 775–783.
[Analyzes the clinical utility of TPMT testing to prevent thiopurine-related toxicity.]
Scott, S. A., et al. (2013). Clinical pharmacogenetics implementation: Approaches, successes, and challenges. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 163C(3), 278–287.
[Explores the operational aspects of incorporating pharmacogenetics into clinical workflows.]
Zhou, S. F., et al. (2008). Polymorphisms of human cytochrome P450 enzymes and their clinical significance: A comprehensive review. Clinical Pharmacokinetics, 47(11), 767–792.
[Comprehensive review of CYP450 genetic polymorphisms and their clinical relevance.]
FDA. (2024). Table of Pharmacogenomic Biomarkers in Drug Labeling.
[An up-to-date resource for pharmacogenomic biomarkers included in FDA-approved drug labels.]
PharmGKB. (2024). Pharmacogenomics Knowledgebase.
[A curated resource providing data on gene-drug relationships and pharmacogenetic pathways.]
Jaja, C., & Burke, W. (2017). Genomics in clinical practice: Population-specific pharmacogenetics. Personalized Medicine, 14(3), 209–219.
[Examines how genetic diversity impacts pharmacogenetic research and clinical practice.]
Hicks, J. K., et al. (2013). Clinical pharmacogenetics implementation: Provider and patient perspectives. Pharmacogenomics, 14(8), 935–945.
[Discusses the challenges of pharmacogenetic implementation from the perspective of stakeholders.]
Amstutz, U., & Ross, C. J. D. (2011). Genetic testing for personalized medicine: TPMT and beyond. Human Genomics and Proteomics, 2011, 1–10.
[Focuses on TPMT and other emerging biomarkers in personalized therapy.]
This work is licensed under a 